VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Dec. 12, 2006) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced publication of a new preclinical study demonstrating that the endogenous neuroprotective protein ADNP (Activity-Dependant Neuroprotective Protein) is essential for brain function and development. Allon's two phase II clinical programs are based on neuroprotective fragments of ADNP. The study was published online this month in the journal Developmental Biology.
